We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AuraVax Therapeutics announced it has entered into an exclusive license option agreement with the University of Houston with respect to the intellectual property covering a novel intranasal vaccine technology.